Search

everythinglearnresearchcommunity

for

Search:↓

Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.

Bimatoprost (Latisse) may help with hair thinning but is expensive and less effective than minoxidil or finasteride. Combining treatments like minoxidil, finasteride, and possibly RU58841 could be more effective for hair loss.

The conversation discusses the effectiveness of Azelaic acid for hair loss, suggesting it may make Finasteride an outdated treatment for male pattern baldness. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses hair loss treatments, specifically Rogaine and Finasteride, with concerns about Finasteride's potential sexual side effects. Users share personal experiences, with some switching to Dutasteride for better results, and others reporting hair regrowth without side effects.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.

The user experienced significant hair thinning and scalp irritation after three months of using topical finasteride. Suggestions include that shedding is normal before regrowth and switching to oral finasteride or addressing scalp inflammation might help.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

A 34-year-old user shared progress pictures after using daily topical minoxidil and oral finasteride for four months, reporting satisfaction with the results and no side effects. The conversation included suggestions for oral minoxidil, debates about the authenticity of the progress photos, and discussions on potential side effects.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.

Asian dermatologists are more open to prescribing finasteride, while in some regions, medications like finasteride and minoxidil can be obtained without a prescription. In Europe, particularly France, there are stricter regulations requiring patients to acknowledge potential side effects, but many people find ways to obtain these treatments through various means.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Hair loss is causing distress and self-esteem issues, with discussions on treatments like finasteride, minoxidil, and hair transplants. Some suggest topical treatments or lifestyle changes, while others stress the importance of confidence and self-acceptance.

A 23-year-old male has been using oral Dutasteride and Minoxidil for six months to address hair loss but sees no improvement. Users suggest continuing the treatment for at least a year, considering a hair transplant, or trying additional treatments like microneedling or topical Minoxidil.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

Finasteride can reduce semen volume due to prostate shrinkage but doesn't affect fertility. To increase semen volume, consider zinc, lecithin, and reducing finasteride dosage.

A 20-year-old is concerned about hair thinning despite using finasteride and minoxidil for over a year. They are advised to manage anxiety, consider therapy, and possibly reassess their treatment plan, while others suggest checking thyroid levels and considering alternative treatments like dutasteride.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.